GPRC5D and Miyoshi myopathy: It is noteworthy that recent research has linked relapses in MM patients receiving anti-GPRC5D CAR T to focal biallelic deletions at the GPRC5D locus, while studies have observed the selective expansion of pre-existing subclones with biallelic GPRC5D loss, highlighting potential mechanisms of resistance to this targeted therapy [96, 97].